BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 27468883)

  • 1. Detection of oncogenic mutations in cervical carcinoma using method High Resolution Melting (HRM).
    Wayhelova M; Mikulasova A; Smetana J; Vallova V; Blazkova D; Filkova H; Moukova L; Kuglik P
    Neoplasma; 2016; 63(5):779-88. PubMed ID: 27468883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutational profiles of marker genes of cervical carcinoma in Bangladeshi patients.
    Sharmin S; Zohura FT; Islam MS; Shimonty A; Khan MA; Parveen R; Sharmin F; Ahsan CR; Islam ABMMK; Yasmin M
    BMC Cancer; 2021 Mar; 21(1):289. PubMed ID: 33736612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma.
    Chau NG; Li YY; Jo VY; Rabinowits G; Lorch JH; Tishler RB; Margalit DN; Schoenfeld JD; Annino DJ; Goguen LA; Thomas T; Becker H; Haddad T; Krane JF; Lindeman NI; Shapiro GI; Haddad RI; Hammerman PS
    Clin Cancer Res; 2016 Jun; 22(12):2939-49. PubMed ID: 26763254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TP53 and PIK3CA gene mutations in adenocarcinoma, squamous cell carcinoma and high-grade intraepithelial neoplasia of the cervix.
    Tornesello ML; Annunziata C; Buonaguro L; Losito S; Greggi S; Buonaguro FM
    J Transl Med; 2014 Sep; 12():255. PubMed ID: 25220666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix.
    Wright AA; Howitt BE; Myers AP; Dahlberg SE; Palescandolo E; Van Hummelen P; MacConaill LE; Shoni M; Wagle N; Jones RT; Quick CM; Laury A; Katz IT; Hahn WC; Matulonis UA; Hirsch MS
    Cancer; 2013 Nov; 119(21):3776-83. PubMed ID: 24037752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma.
    Gleber-Netto FO; Zhao M; Trivedi S; Wang J; Jasser S; McDowell C; Kadara H; Zhang J; Wang J; William WN; Lee JJ; Nguyen ML; Pai SI; Walline HM; Shin DM; Ferris RL; Carey TE; Myers JN; Pickering CR;
    Cancer; 2018 Jan; 124(1):84-94. PubMed ID: 29053175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of molecular targets in vulvar cancers.
    Palisoul ML; Mullen MM; Feldman R; Thaker PH
    Gynecol Oncol; 2017 Aug; 146(2):305-313. PubMed ID: 28536037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Next‑generation sequencing‑based detection of EGFR, KRAS, BRAF, NRAS, PIK3CA, Her‑2 and TP53 mutations in patients with non‑small cell lung cancer.
    Jing C; Mao X; Wang Z; Sun K; Ma R; Wu J; Cao H
    Mol Med Rep; 2018 Aug; 18(2):2191-2197. PubMed ID: 29956783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alterations of the p53 gene in human primary cervical carcinoma with and without human papillomavirus infection.
    Fujita M; Inoue M; Tanizawa O; Iwamoto S; Enomoto T
    Cancer Res; 1992 Oct; 52(19):5323-8. PubMed ID: 1327506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical implication of oncogenic somatic mutations in early-stage cervical cancer with radical hysterectomy.
    Watanabe T; Nanamiya H; Kojima M; Nomura S; Furukawa S; Soeda S; Tanaka D; Isogai T; Imai JI; Watanabe S; Fujimori K
    Sci Rep; 2020 Oct; 10(1):18734. PubMed ID: 33127935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Non-Small Cell Lung Cancer.
    Schrock AB; Welsh A; Chung JH; Pavlick D; Bernicker EH; Creelan BC; Forcier B; Ross JS; Stephens PJ; Ali SM; Dagogo-Jack I; Shaw AT; Li T; Ou SI; Miller VA
    J Thorac Oncol; 2019 Feb; 14(2):255-264. PubMed ID: 30368012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating Tumor DNA Detection in Early-Stage Non-Small Cell Lung Cancer Patients by Targeted Sequencing.
    Chen KZ; Lou F; Yang F; Zhang JB; Ye H; Chen W; Guan T; Zhao MY; Su XX; Shi R; Jones L; Huang XF; Chen SY; Wang J
    Sci Rep; 2016 Aug; 6():31985. PubMed ID: 27555497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted Next-Generation Sequencing-Based Multiple Gene Mutation Profiling of Patients with Rectal Adenocarcinoma Receiving or Not Receiving Neoadjuvant Chemoradiotherapy.
    Chang YK; Tseng HH; Leung CM; Lu KC; Tsai KW
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor receptor pathway mutation and expression profiles in cervical squamous cell carcinoma: therapeutic implications.
    Bumrungthai S; Munjal K; Nandekar S; Cooper K; Ekalaksananan T; Pientong C; Evans MF
    J Transl Med; 2015 Jul; 13():244. PubMed ID: 26209091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ERBB2 mutation: A promising target in non-squamous cervical cancer.
    Xiang L; Jiang W; Ye S; He T; Pei X; Li J; Chan DW; Ngan HYS; Li F; Tao P; Shen X; Zhou X; Wu X; Yang G; Yang H
    Gynecol Oncol; 2018 Feb; 148(2):311-316. PubMed ID: 29279289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary.
    Bochtler T; Reiling A; Endris V; Hielscher T; Volckmar AL; Neumann O; Kirchner M; Budczies J; Heukamp LC; Leichsenring J; Allgäuer M; Kazdal D; Löffler H; Weichert W; Schirmacher P; Stenzinger A; Krämer A
    Int J Cancer; 2020 Jun; 146(11):3053-3064. PubMed ID: 31970771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations of the TP53 gene in adenocarcinoma and squamous cell carcinoma of the cervix: a systematic review.
    Tornesello ML; Buonaguro L; Buonaguro FM
    Gynecol Oncol; 2013 Mar; 128(3):442-8. PubMed ID: 23168175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KRAS and PIK3CA mutations in colorectal adenocarcinomas correlate with aggressive histological features and behavior.
    Jang S; Hong M; Shin MK; Kim BC; Shin HS; Yu E; Hong SM; Kim J; Chun SM; Kim TI; Choi KC; Ko YW; Kim JW
    Hum Pathol; 2017 Jul; 65():21-30. PubMed ID: 28188750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
    Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
    J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients.
    Fathi Z; Mousavi SAJ; Roudi R; Ghazi F
    PLoS One; 2018; 13(7):e0200633. PubMed ID: 30048458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.